We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
NantHealth Inc | NASDAQ:NH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.35 | 1.35 | 1.39 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2018
NantHealth, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-37792 | 27-3019889 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
9920 Jefferson Blvd
Culver City, California 90232
(Address of principal executive offices)(Zip Code)
Registrants telephone number, including area code: (310) 883-1300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
As noted below, on June 8, 2018, our stockholders approved the amendment and restatement of our 2016 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 6,800,000 shares. The Amended and Restated 2016 Equity Incentive Plan is described in more detail in the Companys 2018 Proxy Statement, which was filed with the Securities and Exchange Commission on April 30, 2018. The foregoing description and the summary contained in the Companys 2018 Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Amended and Restated 2016 Equity Incentive Plan, which is attached hereto as Exhibit 10.1.
Item 5.07 Submission of Matters to a Vote of Security Holders.
We held our 2018 annual meeting of stockholders on June 8, 2018 (the Annual Meeting). Of the 108,591,946 shares of our common stock outstanding as of the record date of April 13, 2018, 85,495,301 shares of common stock were represented at the Annual Meeting, either in person or by proxy, constituting approximately 78.7% of the outstanding shares of common stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:
1. | Election of Directors. Each of the following nominees was elected to serve as a director, to hold office until our 2019 annual meeting of stockholders and until his respective successor has been duly elected and qualified, or until such directors earlier death, resignation or removal, based on the following results of voting: |
Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||||
|
||||||||
Patrick Soon-Shiong, M.D. |
75,888,534 | 1,121,731 | 8,485,036 | |||||
Michael S. Sitrick |
75,645,440 | 1,364,825 | 8,485,036 | |||||
Kirk K. Calhoun |
75,970,837 | 1,039,428 | 8,485,036 | |||||
Ron Louks |
74,056,677 | 2,953,588 | 8,485,036 | |||||
Michael Blaszyk |
75,764,411 | 1,245,854 | 8,485,036 |
2. | Approval of Amendment to Companys 2016 Equity Incentive Plan. The amendment to the Companys 2016 Equity Incentive Plan to increase the number of shares of common stock reserved thereunder by 6,800,000 shares was approved based on the following results of voting: |
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
72,645,834 | 4,356,686 | 7,745 | 8,485,036 |
3. | Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018 was ratified based on the following results of the voting: |
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
85,446,224 | 35,035 | 14,042 | - |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. |
Description |
|
10.1 | Amended and Restated 2016 Equity Incentive Plan and forms of award thereunder. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NantHealth, Inc. | ||
By: |
/s/ Paul Holt |
|
Paul Holt Chief Financial Officer |
Date: June 11, 2018
1 Year NantHealth Chart |
1 Month NantHealth Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions